Breathe Well Live Well
|
MediciNova Receives Notice of Patent Allowance for Method of Treating Acute …
NASDAQ SAN DIEGO, Dec. 9, 2012 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), … |
View full post on asthma – Google News
|
MediciNova Reports Third Quarter 2012 Results and Update on MN-221 …
NASDAQ The decrease in research and development expenses was mainly due to a decrease in spending on MN-221 due to the completion of the MN-221-CL-007 trial in patients with acute exacerbations of asthma, partially offset by an increase in spending on our … MediciNova Says Considering Cost, Timing and Design of Future Trials; FDA … |
View full post on asthma – Google News
|
MediciNova Receives a Notice of European Patent Allowance for Treating …
NASDAQ MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis … MediciNova Receives Notice of European Patent Allowance for Treating … |
View full post on asthma – Google News
|
MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat …
NASDAQ "There is a significant unmet medical need for an IV agent like MN-221 for asthma and COPD patients who are admitted to the ER due to a severe episode that is unresponsive to standard therapy," said Kazuko Matsuda, M.D., Ph.D., M.P.H, Chief Medical … |
View full post on asthma – Google News
|
MediciNova Enters Into a $20 Million Common Stock Purchase Agreement With …
NASDAQ MediciNova will use the net proceeds from any sales of its stock to advance MediciNova's development activities for its lead programs, MN-221 (bedoradrine sulfate) in development for the treatment of acute asthma and chronic obstructive pulmonary … |
View full post on asthma – Google News
|
MediciNova Asthma Compound Poised for Late-Stage Trials
San Diego Business Journal By Julie Gallant Tuesday, May 29, 2012 Local biopharmaceutical company MediciNova Inc. received enough positive news from a phase 2b clinical trial evaluating its MN-221 asthma compound to pursue planning for phase 3 trials. |
View full post on asthma – Google News
|
MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma …
FierceBiotech MediciNova intends to design pivotal trial(s) that will include technological and operational improvements and further controls for medications that are not typically used in the treatment of acute exacerbations of asthma and were over-represented in … MediciNova Reports Results Of A Phase 2b Trial Of MN-221 In Asthma Exacerbations |
View full post on asthma – Google News
|
MediciNova shares plunge as asthma drug fails in Ph IIb trial
The Pharma Letter MediciNova intends to design pivotal trial(s) that will include technological and operational improvements and further controls for medications that are not typically used in the treatment of acute exacerbations of asthma and were over-represented in … |
View full post on asthma – Google News
|
MediciNova shares crash after lead asthma drug fails IIb trial
FierceBiotech MediciNova's ($MNOV) shares crashed after the San Diego-based biotech said its Phase IIb study of an acute asthma drug failed to hit the primary endpoint. And while the CEO tried to put the data in context, offering reasons for optimism for a planned … MediciNova asthma drug fails trial; shares crash MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma … |
View full post on asthma – Google News
|
MediciNova asthma drug fails trial; shares crash
Reuters (Reuters) – Biopharmaceutical company MediciNova Inc said its experimental asthma drug failed to meet the main goal of a second mid-stage trial, sending its shares down as much as 51 percent in extended trade. MediciNova, which is testing MN-221 as a … MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma … MediciNova (MNOV) Says Results of Phase 2B Trial of MN-221 Didn't Meet Primary … |
View full post on asthma – Google News